• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.

作者信息

Wintering Astrid, Ishiyama Kenichi, Tamaki Stanley, Tamaki Courtney, Fandel Joshua, Ji Lingyun, Wood Brent L, Shah Nirali N, Yuan Constance M, O'Brien Maureen M, Loh Mignon L, Diaz-Flores Ernesto

机构信息

Department of Pediatrics, Benioff Children's Hospital, and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA.

出版信息

Blood Adv. 2023 Jan 24;7(2):251-255. doi: 10.1182/bloodadvances.2021006810.

DOI:10.1182/bloodadvances.2021006810
PMID:35500285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9840233/
Abstract
摘要

相似文献

1
CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.CD22低表达/Bcl-2高表达表明复发/难治性急性淋巴细胞白血病患者对奥英妥珠单抗反应不佳。
Blood Adv. 2023 Jan 24;7(2):251-255. doi: 10.1182/bloodadvances.2021006810.
2
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.奥英妥珠单抗在复发/难治性急性淋巴细胞白血病治疗中的作用。
Immunotherapy. 2016 Feb;8(2):135-43. doi: 10.2217/imt.15.108. Epub 2016 Jan 18.
3
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.英妥昔单抗奥唑米星在复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤中的群体药代动力学。
J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):211-222. doi: 10.1007/s10928-018-9614-9. Epub 2019 Mar 11.
4
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast.依妥珠单抗治疗新诊断的老年急性淋巴细胞白血病-播客。
Target Oncol. 2024 Mar;19(2):135-141. doi: 10.1007/s11523-023-01023-y. Epub 2024 Mar 8.
5
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.奥英妥珠单抗治疗急性淋巴细胞白血病
Front Biosci (Elite Ed). 2014 Jan 1;6(1):40-5. doi: 10.2741/e688.
6
Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.奥英妥珠单抗用于治疗急性淋巴细胞白血病患者。
Drugs Today (Barc). 2017 Dec;53(12):653-665. doi: 10.1358/dot.2017.53.12.2737934.
7
Inotuzumab Ozogamicin: First Pediatric Approval.依妥珠单抗奥佐米星：首款获儿科批准的药物。
Paediatr Drugs. 2024 Jul;26(4):459-467. doi: 10.1007/s40272-024-00634-w. Epub 2024 May 23.
8
Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.奥英妥珠单抗在复发急性淋巴细胞白血病非移植患者中的临床意义：4例报告
Intern Med. 2020 Aug 15;59(16):2047-2051. doi: 10.2169/internalmedicine.4440-20. Epub 2020 May 8.
9
Antibody based therapy in relapsed acute lymphoblastic leukemia.抗体药物治疗复发急性淋巴细胞白血病。
Best Pract Res Clin Haematol. 2020 Dec;33(4):101225. doi: 10.1016/j.beha.2020.101225. Epub 2020 Nov 18.
10
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.INO-VATE 试验中的伊妥珠单抗奥唑米星治疗复发/难治性急性淋巴细胞白血病：根据基线 CD22 评估 CD22 药效动力学、疗效和安全性
Clin Cancer Res. 2021 May 15;27(10):2742-2754. doi: 10.1158/1078-0432.CCR-20-2399. Epub 2021 Feb 18.

引用本文的文献

1
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.DNTT介导的DNA损伤反应驱动B细胞急性淋巴细胞白血病中奥英妥珠单抗耐药。
Blood. 2025 Mar 13;145(11):1182-1194. doi: 10.1182/blood.2024026085.
2
Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.裸抗体和抗体药物偶联物：儿童急性淋巴细胞白血病的靶向治疗。
Haematologica. 2024 Jun 1;109(6):1700-1712. doi: 10.3324/haematol.2023.283815.
3
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions.

本文引用的文献

1
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.Inotuzumab Ozogamicin 治疗儿童和青少年复发/难治性 B 细胞急性淋巴细胞白血病的 II 期临床试验：儿童肿瘤学组协议 AALL1621。
J Clin Oncol. 2022 Mar 20;40(9):956-967. doi: 10.1200/JCO.21.01693. Epub 2022 Jan 10.
2
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.INO-VATE 试验中的伊妥珠单抗奥唑米星治疗复发/难治性急性淋巴细胞白血病：根据基线 CD22 评估 CD22 药效动力学、疗效和安全性
Clin Cancer Res. 2021 May 15;27(10):2742-2754. doi: 10.1158/1078-0432.CCR-20-2399. Epub 2021 Feb 18.
3
依妥珠单抗奥滨尤妥珠单抗治疗成人急性淋巴细胞白血病：既往进展、当前研究及未来方向。
J Hematol Oncol. 2024 May 11;17(1):32. doi: 10.1186/s13045-024-01552-7.
4
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.BH3模拟物用于复发和难治性成人急性淋巴细胞白血病：一项校园ALL真实世界研究
Haematologica. 2024 Mar 1;109(3):988-993. doi: 10.3324/haematol.2023.283684.
5
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.依妥珠单抗奥滨尤妥珠单抗在 B 细胞前体急性淋巴细胞白血病中的疗效、毒性及实际考虑因素。
Front Immunol. 2023 Aug 3;14:1237738. doi: 10.3389/fimmu.2023.1237738. eCollection 2023.
6
Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia.儿童肿瘤学组研究蓝图：急性淋巴细胞白血病。
Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30585. doi: 10.1002/pbc.30585. Epub 2023 Jul 25.
7
Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with pathway alterations.维奈托克在伴有通路改变的成人复发/难治性费城阴性急性淋巴细胞白血病中的持久反应。
Front Cell Dev Biol. 2023 May 23;11:1165308. doi: 10.3389/fcell.2023.1165308. eCollection 2023.
Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.维奈托克和地塞米松与奥英妥珠单抗诱导的B系急性淋巴细胞白血病DNA损伤信号协同作用。
Blood. 2021 May 13;137(19):2657-2661. doi: 10.1182/blood.2020008544.
4
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).一项评估奥加米妥珠单抗治疗儿童复发/难治性急性淋巴细胞白血病的 1 期临床研究（ITCC-059 研究）。
Blood. 2021 Mar 25;137(12):1582-1590. doi: 10.1182/blood.2020007848.
5
Tissue Determinants of Human NK Cell Development, Function, and Residence.人类自然杀伤细胞发育、功能和归巢的组织决定因素。
Cell. 2020 Feb 20;180(4):749-763.e13. doi: 10.1016/j.cell.2020.01.022. Epub 2020 Feb 13.
6
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.依妥珠单抗：从临床前研发到在 B 细胞急性淋巴细胞白血病中的成功。
Blood Adv. 2019 Jan 8;3(1):96-104. doi: 10.1182/bloodadvances.2018026211.
7
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.依妥珠单抗奥滨尤妥珠单抗治疗复发/难治性儿童急性淋巴细胞白血病。
Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28.
8
Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.奥英妥珠单抗治疗复发的B细胞急性淋巴细胞白血病
Eur J Haematol. 2017 May;98(5):425-434. doi: 10.1111/ejh.12862. Epub 2017 Mar 9.
9
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.儿童急性淋巴细胞白血病异种移植模型对维奈托克的反应揭示了MLL重排白血病的敏感性。
Blood. 2016 Sep 8;128(10):1382-95. doi: 10.1182/blood-2016-03-707414. Epub 2016 Jun 24.
10
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.